Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic lymphoproliferative disorders

E Montserrat1

  • 1Department of Hematology, Hospital Clinic, Barcelona, Spain.

Current Opinion in Oncology
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Advances in classifying and treating chronic lymphoproliferative disorders, including B-cell chronic lymphocytic leukemia, offer new hope. Improved understanding of molecular drivers and new therapies are leading to sustained remissions and potential cures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation.

Bone marrow transplantation·2020
Same author

Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity.

Leukemia·2017
Same author

appendix 6: Chronic lymphocytic leukaemia: eUpdate published online September 2016 (http://www.esmo.org/Guidelines/Haematological-Malignancies).

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Interferon alpha-2b for Essential Thrombocythaemia: Results in 13 Previously Untreated Patients.

Leukemia & lymphoma·2016
Same author

Chronic Lymphocytic Leukemia in Younger Adults: Preliminary Results of a Study Based on 454 Patients-IWCLL/Working Group.

Leukemia & lymphoma·2016
Same journal

Artificial intelligence-augmented robotic surgery in gynecologic oncology: intraoperative assistance and analytics.

Current opinion in oncology·2026
Same journal

Artificial intelligence in cervical cancer screening and triage: a role-stratified systematic review and bivariate meta-analysis.

Current opinion in oncology·2026
Same journal

Deep learning assisting the surgical management of gynecologic cancers.

Current opinion in oncology·2026
Same journal

Pain management in pancreatic cancer: time to change our strategy!

Current opinion in oncology·2026
Same journal

Systemic radionuclide treatments in gastro-entero-pancreatic neuroendocrine tumours.

Current opinion in oncology·2026
Same journal

5-Fluorouracil at seventy: still attractive but barely understood. A cautionary tale for drug development.

Current opinion in oncology·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic lymphoproliferative disorders (CLPDs) are a diverse group of diseases with varied clinical outcomes.
  • B-cell chronic lymphocytic leukemia (CLL) is the most common CLPD and serves as a model for studying these conditions.
  • Recent years have seen significant progress in understanding CLPD classification, biology, and treatment.

Purpose of the Study:

  • To review recent advancements in the classification, molecular biology, and therapeutic strategies for CLPDs.
  • To differentiate CLL from similar entities like splenic lymphoma with villous lymphocytes and mantle-cell lymphoma.
  • To highlight the impact of novel treatments on patient outcomes.

Main Methods:

  • Review of current literature on CLPD classification and diagnosis.

Related Experiment Videos

  • Analysis of molecular mechanisms underlying CLPD pathogenesis, including gene mutations and cytokine involvement.
  • Evaluation of emerging therapeutic options such as purine analogues and stem cell transplantation.

    • Main Results:

    • Distinguishing CLL from confounding entities is crucial due to differing prognoses and treatments.
    • Key molecular factors like CCND1 gene overexpression, bcl-2/bax expression, and p53 mutations are increasingly understood.
    • Cytokines play a role in CLPD pathogenesis by influencing cell growth and apoptosis.
    • New treatments are shifting focus from symptom palliation to achieving complete remissions and cures.

    Conclusions:

    • Progress in classification and understanding molecular underpinnings has improved CLPD management.
    • Novel therapies offer the potential for sustained remissions and cures in some CLPDs.
    • Accurate diagnosis and tailored treatment are essential for optimizing patient outcomes in CLPDs.